In your submission you recommend mandatory generic substitution, which you also mentioned in your remarks. Some witnesses have come before this committee and warned us that measures like that—and in fact a universal pharmacare system itself—would restrict choice for patients and potentially undermine access to quality therapies.
What is your response to those criticisms?